This review will explore the evolving role of BCL-2 inhibition in AL amyloidosis and PCL, with a particular focus on venetoclax, by synthesizing existing data and identifying knowledge gaps, thereby offering insights to guide future research and clinical practice in these difficult-to-treat malignancies. This evidence concerns the gene BCL2 and AL amyloidosis.